Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Mersana (MRSN) PT Raised to $15 at Citi, Opens Catalyst Watch
May 10, 2023 3:24 PM EDTCiti analyst Ashiq Mubarack raised the price target on Mersana (NASDAQ: MRSN) to $15.00 (from $12.00) while maintaining a Buy rating.
The analys topens a 90-day upside catalyst watch commenting "In mid-2023, MRSN will share topline results from the pivotal UPLIFT Ph2 trial evaluating UpRi in... More
